The question bank is the fastest way to start, but PMHNP Helper also includes board-review planning, student resources, and plain-English guidance for psychiatric nurse practitioner students who are still learning the exam landscape.
advanceddual diagnosisbipolar II disorderalcohol use disorderlithiumAUDITPHQ-9motivational enhancement therapyintegrated treatment
A 38-year-old male with bipolar II disorder and moderate alcohol use disorder has been engaged in an integrated dual-diagnosis treatment program for 16 weeks. His treatment includes lithium 900 mg daily with a trough level of 0.72 mEq/L, weekly motivational enhancement therapy, and participation in a relapse prevention group. At baseline, his PHQ-9 was 18, his Alcohol Use Disorders Identification Test (AUDIT) score was 26, and he reported consuming an average of 28 standard drinks per week. At today's evaluation, his PHQ-9 is 11, AUDIT score is 14, and he reports consuming eight standard drinks per week, concentrated on weekends. He has had no hypomanic episodes during treatment. He reports improved work attendance but continues to drink three to four beers every Friday and Saturday evening, stating he feels this is controlled and social. His liver enzymes are normalizing with GGT decreasing from 86 to 42 U/L. The PMHNP is evaluating the overall treatment response for both disorders simultaneously. Which of the following best represents the appropriate evaluation?
Explanation
Integrated dual-diagnosis treatment evaluation requires simultaneously assessing both conditions and their interactions rather than evaluating each disorder in isolation. Continued alcohol use, even at substantially reduced levels, can confound psychiatric treatment response through circadian disruption, sleep impairment, and neurobiological interactions with mood stabilizer efficacy.
Key Takeaway
When evaluating dual-diagnosis treatment response, the PMHNP must assess the interaction between residual substance use and incomplete psychiatric symptom improvement, as continued alcohol use can confound mood stabilizer efficacy even when consumption has been substantially reduced.